Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021
Twist Bioscience Corporation (NASDAQ: TWST) has announced plans to release its financial results for the fiscal 2021 second quarter on May 6, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The financial results will be accessible on the company's website under Investor Relations. Twist Bioscience is focused on pioneering DNA synthesis technology, catering to diverse industries including healthcare and agriculture.
- Twist Bioscience is a rapidly growing synthetic biology company.
- Company offers a unique DNA synthesis platform that could enhance market position.
- None.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2021 second quarter ended March 31, 2021, following the close of market on Thursday, May 6, 2021. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.
The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 4647559. A telephonic replay of the conference call will be available beginning approximately four hours after the call through May 20, 2021 and may be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay conference ID is 4647559. The webcast replay will be available for two weeks.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005217/en/
FAQ
When will Twist Bioscience announce its fiscal Q2 2021 financial results?
What time is the conference call for Twist Bioscience's financial results?
How can investors access the financial results of Twist Bioscience?
What is the focus of Twist Bioscience's technology?
